Get started
Work

Abstract RF6-03: Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer: Interim analysis of a randomized, open-label, phase 3 trial

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-rf6-03
Authors: X. Hu, J. Yu, T. Sun, Q. Zhang, H. Li, J. Yao, Y. Shi, T. Wu, X. Jia, Y. Shi, S. Ding, W. Chen, Y. Zeng, X. Zeng, Y. Yin, J. Wu, J. Sun, D. Luo, J. Nie, F. Li, Y. Liu, Z. Zhang, C. Yuan, C. Yang, H. Yang, C. Li, X. Ling, X. Wu, G. Li, Z. Li, Z. Pan, J. Zhang, Q. Zhou
Institutions: Fudan University Shanghai Cancer Center, Shandong Tumor Hospital, Liaoning Cancer Hospital & Institute, China Medical University, Harbin Medical University, Peking University Cancer Hospital, Huazhong University of Science and Technology, Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital, Sun Yat-sen University Cancer Center, Tianjin Medical University, The First People's Hospital of Changde, Fujian Medical University, Fujian Provincial Cancer Hospital, Chongqing University, Chongqing Cancer Hospital, Jiangsu Province Hospital, Meizhou City People's Hospital, Anyang Tumor Hospital, First People’s Hospital of Zunyi, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Jilin Province Tumor Hospital, Ningxia Medical University, Ningxia Medical University General Hospital, Yue Bei People's Hospital, Hebei University, First Hospital of Lanzhou University, Hubei Cancer Hospital
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129634473
Cites:
Cited by: 2
Related to: